Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study-Reference-Cited by-同舟云学术

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

Published:2015-06-21 Issue:23 Volume:21 Page:7281-7288
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Antonuzzo Lorenzo,Giommoni Elisa,Pastorelli Davide,Latiano Tiziana,Pavese Ida,Azzarello Domenico,Aieta Michele,Pastina Ilaria,Fabio Francesca Di,Bertolini Alessandro,Corsi Domenico Cristiano,Mogavero Selene,Angelini Valentina,Pazzagli Mario,Costanzo Francesco Di

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference18 articles.

1. Monoclonal antibodies in gastrointestinal cancers

2. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

3. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

4. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

5. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis;Journal of Pharmaceutical Policy and Practice;2024-06-05

2. Elevated expression of NXPH4 is associated with poor prognosis and immune infiltration in colorectal cancer patients;2023-11-08

3. Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer;Anti-Cancer Drugs;2022-11-15

4. Colorectal cancer management: strategies in drug delivery;Expert Opinion on Drug Delivery;2022-06-03

5. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer;Frontiers in Immunology;2021-12-02